Skip to ContentSkip to Navigation
About us Practical matters How to find us prof. dr. E. (Edo) Vellenga


Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial

Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study

Presence of mutant p53 increases stem cell frequency and is associated with reduced binding to classic TP53 binding sites in cell lines and primary AMLs

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation

Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality

Read more